AstraZeneca’s Oncology Drives 16% Growth, Boosts Q3 Earnings

Bullish Gator

CEO Pascal Soriot says oncology growth lifted Q3 results 16%, highlights cancer vaccine plans and an Oracle AI clinical-trial partnership.

Editorial companion

What stands out

Pascal Soriot, AstraZeneca’s CEO, says oncology sales powered a 16 percent lift in third-quarter results and highlights work on cancer vaccines plus a clinical-trial partnership with Oracle to apply AI. The clip matters because a drugmaker touting double-digit growth for its highest-margin franchise is news in and of itself, and because the Oracle tie-up shifts the story from pills to data, clinical trials that run faster or smarter can change timelines for many drugs in development.